{
    "nctId": "NCT00558272",
    "briefTitle": "Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease",
    "officialTitle": "A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Prostate Cancer, Bone Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 139,
    "primaryOutcomeMeasure": "Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects 18 years or older with Prostate Cancer or Breast Cancer with Metastatic Bone Disease Have evidence of recurrence or disease progression\n* At least one radiographically confirmed metastatic bone lesion\n* No change of cancer therapy for at least 8 weeks before randomization\n\nExclusion Criteria:\n\n* Have had any prior exposure to bisphosphonate\n* Have had hip fractures or bilateral hip prothesis fracture of any kind or surgery to bone within the past 12 months\n* Inadequate renal function or low haemoglobin\n* Inadequate liver function as demonstrated by serum bilirubin \u22652 times the upper limits of reference range (ULRR) or by alanine aminotransferase (ALT), aspartate aminotransferase(AST) or ALP \u22652.5 times the ULRR (\u22655 times the ULRR in the presence of liver metastases). If bone metastases are present and liver function is otherwise considered adequate by the investigator then elevated ALP will not exclude the patient.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}